Partial federal government shutdown
HCA does not anticipate any immediate impacts to our services or disruption to provider payments at this time. We will continue to monitor the situation and share updates if anything changes.
Cell free DNA prenatal screening for chromosomal aneuploidies (cfDNA)
Cell free fetal DNA (cfDNA) screening is a form of noninvasive prenatal testing (NIPT) used to determine the risk that a fetus will be born with certain genetic abnormalities.
Status: Decision completed
Why is cell free DNA prenatal screening being reviewed?
There is uncertainty about the appropriateness of cfDNA screening for some populations, including those at low risk for common fetal genetic abnormalities. This topic was selected for a health technology assessment because of medium concerns for the safety and efficacy of cfDNA screening in the general population and high concern for cost.
Primary criteria ranking
- Safety = Medium
- Efficacy = Medium
- Cost = High
Documentation
| Type | Materials |
|---|---|
| Assessment (2019) |
Assessment timeline
- Draft key questions published: July 9, 2019
- Public comment period: July 10 to 23, 2019
- Final key questions updated: August 26, 2019
- Draft report published: October 22, 2019
- Public comment period: October 23 to November 21, 2019
- Final report published: December 13, 2019
- HTCC public meeting: January 17, 2020